Conjugate Vaccine Market

Conjugate Vaccine Market to be Driven by the Favourable Government Initiatives in the Forecast Period of 2023-2031

The new report by Expert Market Research titled, ‘Global Conjugate Vaccine Market Share, Report and Forecast 2023-2031’, gives an in-depth analysis of the global conjugate vaccine market, assessing the market based on its segments like types, disease indications, diseases, pathogen types, patients, and major regions.

The report tracks the latest trends in the industry and studies their impact on the overall market. It also assesses the market dynamics, covering the key demand and price indicators, along with analysing the market based on the SWOT and Porter’s Five Forces models.

 Conjugate Vaccine Market Size, Share, Trends, Industry Report, Key Player, Major Segments, and Forecast

The key highlights of the report include:

Market Overview (2016-2031)

  • Historical Market Size (2022): USD 16 Billion
  • Forecast CAGR (2023-2031): 11%
  • Forecast Market Size (2031): USD 40.9 Billion

The pandemic bolstered the conjugate vaccine market in the historical period as some biotechnology companies researched to develop vaccines to prevent the spread of COVID-19. For instance: in July 2021, BioFarma, a corporation of Cuba, announced Soberana 2 vaccine against COVID 19 spread. The increasing prevalence of diseases and the use of conjugate vaccines for adults worldwide are driving the market growth of the conjugate vaccines industry.

Get a Free Sample Report with Table of Contents:

In addition, the rising regulatory approvals by organisations, such as the World Health Organisation and the growing awareness about the efficiency of the vaccine is also resulting in the steady growth of the market. The expanding geriatric population and their susceptibility to the diseases are providing impetus to the growth of the conjugate vaccine industry.

 Conjugate Vaccine Market Definition and Major Segments

The conjugate vaccine combines weak antigens and strong antigens to enable the immune system to strongly respond to the weak antigen by producing T cells and antibodies.  The doses are administered to immunise the population against diseases, like influenza, diphtheria tetanus and pertussis, and meningococcal, among others.

The conjugate vaccine industry, by type, is divided into

  • Monovalent Conjugate Vaccine
  • Multivalent Conjugate Vaccine

Based on disease indication, the market is segmented into:

  • Pneumococcal
  • Influenza
  • Diphtheria Tetanus and Pertussis (DTP)
  • Meningococcal
  • Others

On the basis of pathogen type, the market is divided into:

  • Bacterial Conjugate Vaccine
  • Viral Conjugate Vaccine
  • Combined Conjugate Vaccine

Based on patient, the market is segmented into:

  • Adults
  • Paediatrics

The regional markets for conjugate vaccine include:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

Read Full Report with Table of Contents

 Conjugate Vaccine Market Trends

The efforts taken by governments across the world to immunise the population to reduce mortality and morbidity is leading to the incremental development of the conjugate vaccine industry. The Government of India launched Pneumococcal Conjugate Vaccine (PCV) in May 2017 to reduce infant mortality and morbidity caused by pneumococcal pneumonia in Bihar, Himachal Pradesh, Madhya Pradesh, 19 districts of Uttar Pradesh and 18 districts of Rajasthan. The initiatives of industry players in launching vaccines and getting them approved by regulatory bodies are also resulting in the expansion of the conjugal vaccine industry. For instance: in July 2021, Merck declared the approval of VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) by the United States Food and Drug Administration against invasive pneumococcal disease in adults 18 years and older. The ongoing research activities to develop efficient vaccines is expected to augment the conjugate vaccine industry in the forecast period.

Key Market Players

The major players in the market are Serum Institute of India Pvt., Ltd., Groupe Sanofi, Pfizer Inc., Novartis AG, and Bharat Biotech Ltd., among others. The report covers the market shares, capacities, plant turnarounds, expansions, investments and mergers and acquisitions, among other latest developments of these market players.

About Us:

Expert Market Research (EMR) is leading market research company with clients across the globe. Through comprehensive data collection and skillful analysis and interpretation of data, the company offers its clients extensive, latest, and actionable market intelligence which enables them to make informed and intelligent decisions and strengthen their position in the market. The clientele ranges from Fortune 1000 companies to small and medium scale enterprises.

EMR customises syndicated reports according to clients’ requirements and expectations. The company is active across over 15 prominent industry domains, including food and beverages, chemicals and materials, technology and media, consumer goods, packaging, agriculture, and pharmaceuticals, among others.

Over 3000 EMR consultants and more than 100 analysts work very hard to ensure that clients get only the most updated, relevant, accurate and actionable industry intelligence so that they may formulate informed, effective and intelligent business strategies and ensure their leadership in the market.

Media Contact:

Company Name: Claight Corporation
Contact Person:  Jhon Roy, Corporate Sales Specialist – U.S.A.
Toll Free Number: +1-415-325-5166 | +44-702-402-5790
Address: 30 North Gould Street, Sheridan, WY 82801, USA

Leave a Reply

Your email address will not be published. Required fields are marked *